Cargando…
Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4
The effect of in vivo administration of monoclonal anti-L3T4 antibody on the development of murine collagen-induced arthritis (CIA) was assessed. Treatment with anti-L3T4 resulted in a greater than 90% depletion of L3T4+ T cells in lymph nodes and spleen, an effect that appears entirely reversed 30...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1985
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187818/ https://www.ncbi.nlm.nih.gov/pubmed/3928802 |
_version_ | 1782146263029907456 |
---|---|
collection | PubMed |
description | The effect of in vivo administration of monoclonal anti-L3T4 antibody on the development of murine collagen-induced arthritis (CIA) was assessed. Treatment with anti-L3T4 resulted in a greater than 90% depletion of L3T4+ T cells in lymph nodes and spleen, an effect that appears entirely reversed 30 d after treatment. Administration of anti- L3T4 before immunization with type II collagen resulted in a significant decrease in arthritis incidence and delayed onset of the disease while treatment begun after a strong anticollagen IgG humoral response was underway was not effective in altering disease expression. These results suggest a prominent role for L3T4+ T cells in the pathogenesis of CIA. |
format | Text |
id | pubmed-2187818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1985 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-21878182008-04-17 Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4 J Exp Med Articles The effect of in vivo administration of monoclonal anti-L3T4 antibody on the development of murine collagen-induced arthritis (CIA) was assessed. Treatment with anti-L3T4 resulted in a greater than 90% depletion of L3T4+ T cells in lymph nodes and spleen, an effect that appears entirely reversed 30 d after treatment. Administration of anti- L3T4 before immunization with type II collagen resulted in a significant decrease in arthritis incidence and delayed onset of the disease while treatment begun after a strong anticollagen IgG humoral response was underway was not effective in altering disease expression. These results suggest a prominent role for L3T4+ T cells in the pathogenesis of CIA. The Rockefeller University Press 1985-09-01 /pmc/articles/PMC2187818/ /pubmed/3928802 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Articles Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4 |
title | Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4 |
title_full | Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4 |
title_fullStr | Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4 |
title_full_unstemmed | Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4 |
title_short | Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4 |
title_sort | prevention of type ii collagen-induced arthritis by in vivo treatment with anti-l3t4 |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187818/ https://www.ncbi.nlm.nih.gov/pubmed/3928802 |